top of page

ASGCT 2026: Tenaya Therapeutics today presented interim clinical data for its gene therapy for patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by PKP2 mutations

  • May 15
  • 1 min read

CEO Faraz Ali walks us through the data, which included six patients, and sets the table for a future update on a gene therapy program for hypertrophic cardiomyopathy that will be announced before the end of the quarter.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page